A Phase 1, Double-blind, Randomized, Placebo-controlled, Multiple Ascending Dose Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TD−1439 in Healthy Subjects
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 19 Apr 2017
At a glance
- Drugs TD 1439 (Primary)
- Indications Cardiovascular disorders; Kidney disorders
- Focus Adverse reactions
- Sponsors Theravance Biopharma
- 30 Mar 2017 Status changed from recruiting to active, no longer recruiting.
- 27 Feb 2017 According to a Theravance Biopharma media release, expected completion of this trial in 1H 2017.
- 08 Nov 2016 According to Theravance Biopharma media release, data expected in first half of 2017.